Revvity, Inc.

Company facts

Industry

Laboratory Analytical Instruments

Headquarters

Waltham, Massachusetts

Most recent report

8-K, filed Nov 3, 2026

Incorporated

Massachusetts

Filings on record

1,000+ filings

On EDGAR

CIK 31791

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jul 2026 10-Q

SECSift found 2 of 11 sections worth reading, with 1 positive, 6 notable, and 2 negative flags.

• Financial Statements (Item 1)

  Financial statements with restructuring surge, debt repayment, and China divestiture.
  Notable

  • Repaid €500M 1.875% notes due 2026 in July 2026, reducing debt by $571.2M.
  • Entered agreement to divest Immunodiagnostics China (~6% of FY2025 revenue), close by end 2027.

• Management's Discussion (Item 2)

  Tariff refunds, restructuring surge, €500M debt repaid, segment divergence all company-specific.
  Positive

  • Diagnostics segment operating income rose 26% to $112.9M in Q2, with margin up 520 bps.
  Notable

  • Gross margin rose 260 bps to 57.1% in Q2, primarily from $16.2M in tariff refunds received.
  • Restructuring costs hit $35.5M in Q2, up from $11.2M, affecting 3% of the workforce in the quarter.
  • R&D spending cut 8% to $49.0M in Q2, driven by cost containment initiatives.
  • Share buybacks slowed to just $7.8M in Q2 vs $79.0M in Q1; $792.7M remains authorized.
  Negative

  • Operating margin fell from 12.6% to 12.2% in Q2 as restructuring and digital spending weighed.
  • Life Sciences revenue fell 2% to $358.7M in Q2, driven by a $10.2M drop in Software revenue.

What changed: Jul 2026 vs. Apr 2026

About 10% of RVTY's Jul 2026 10-Q is new information. 30 paragraphs were added, 95 changed, and 26 removed. Below are the most important lines SECSift identified.

• Item 2 39
• Item 1 32
• Item 6 13
• Item 1A 7
• Item 5 4
• Item 4 2
• Item 3 1